Table 3 Discrimination and reclassification improvements of mtDNA 8-OHdG beyond the 2013 ACC/AHA PCE and the FRS in 1920 patients with T2DM
Risk estimates | ACC/AHA 2013 PCE + mtDNA 8-OHdG | FRS + mtDNA 8-OHdG | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
< 20% | 20–50% | > 50% | Total | Reclassified | < 20% | 20–50% | > 50% | Total | Reclassified | |
Individuals without obstructive CAD, No. | ||||||||||
< 20% | 268 | 23 | 0 | 291 | 8% | 352 | 10 | 0 | 362 | 3% |
20–50% | 68 | 275 | 41 | 384 | 28% | 59 | 191 | 14 | 264 | 28% |
> 50% | 0 | 48 | 143 | 191 | 25% | 0 | 27 | 213 | 240 | 11% |
Total | 336 | 346 | 184 | 866 | 411 | 228 | 227 | 866 | ||
Individuals with obstructive CAD, No. | ||||||||||
< 20% | 125 | 30 | 3 | 158 | 21% | 105 | 7 | 0 | 112 | 6% |
20–50% | 35 | 288 | 82 | 405 | 29% | 30 | 205 | 41 | 276 | 26% |
> 50% | 0 | 35 | 456 | 491 | 7% | 0 | 31 | 635 | 666 | 5% |
Total | 160 | 353 | 541 | 1054 | 135 | 243 | 676 | 1054 | ||
Estimate (95% CI) | P value | Estimate (95% CI) | P value | |
|---|---|---|---|---|
Δ C-statistic | 0.024 (0.013–0.035) | < 0.001 | 0.010 (0.003–0.017) | 0.003 |
IDI | 0.020 (0.014–0.026) | < 0.001 | 0.014 (0.001–0.019) | < 0.001 |
NRI continuous | 0.299 (0.210–0.388) | < 0.001 | 0.196 (0.107–0.286) | < 0.001 |
NRI categorical | 0.103 (0.064–0.142) | < 0.001 | 0.059 (0.029–0.090) | < 0.001 |